Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update.
Ther Adv Neurol Disord
January 2025
EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population.
Objectives: To describe the main features of the CLEAR study design, including the data sources and the methodological approach, and provide a status update.
Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
Mult Scler
January 2025
Radiology Department, Shamir Medical Center, Tzrifin, Israel.
Background: Measuring brain volume changes over time is an objective and dependable surrogate marker for the pathological processes that damage the brain in relapsing-remitting multiple sclerosis (RRMS). These measures are particularly valuable for monitoring the long-term impact of immunomodulatory treatments such as cladribine.
Objectives: To evaluate the long-term impact of oral cladribine treatment on brain volume loss in patients with RRMS.
Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries.
Mult Scler Relat Disord
January 2025
Merck KgaA, Darmstadt, Germany. Tronador 4890 5th floor (C1430DNN), CABA, Argentina. Electronic address:
The use of additional cladribine tablets treatment courses is becoming an option in patients with multiple sclerosis (MS) showing disease activity after treatment initiation. Despite the availability over the past year of several expert opinion guidance on the subject, there is a need for real-world assessment of the efficacy and safety of cladribine tablets in these patients. Thus, the aim of the present retrospective observational study is to describe the characteristics of patients that received additional treatment courses within the cohort of cladribine tablets-treated MS patients enrolled in the patient support program (PSP) Adveva® in Latin America countries.
View Article and Find Full Text PDFErdheim Chester Disease with Calvarial Involvement: A rare case of Histiocytosis.
Turk Neurosurg
March 2024
SBÜ Gaziosmanpaşa Eğitim ve Araştırma Hastanesi.
Erdheim-Chester Disease is a rare systemic xanthogranulomatous infiltrating disease, characterized by lipid-laden histiocytes accumulating in various organs and almost always in bones. Etiology of the disease is still unknown. It may involve various organs and systems, such as musculoskeletal, cardiac, pulmonary, renal, gastrointestinal and central nervous system (CNS) as well as the skin.
View Article and Find Full Text PDFReal world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers.
Mult Scler Relat Disord
January 2025
John L Trotter Multiple Sclerosis Center, Washington University, St. Louis, Missouri, USA.
Background: Cladribine tablets (CladT) are a multiple sclerosis (MS) disease-modifying therapy (DMT) with safety and efficacy established in the CLARITY trial and extension. A better understanding of the role of CladT in real-world populations is needed, including the clinical and radiographic trajectories of persons with MS (PwMS) treated with CladT and how CladT compares to other MS DMTs.
Methods: PwMS receiving CladT at 4 tertiary MS centers were identified and characterized.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!